Eun Yang
Stock Analyst at Jefferies
(0.06)
# 3,810
Out of 4,829 analysts
43
Total ratings
16.67%
Success rate
-45.31%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $310.80 | +39.00% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $2.32 | +244.83% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $4.37 | +517.85% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.30 | +398.50% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $35.68 | -7.51% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.77 | +1,481.92% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $18.99 | +42.18% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.82 | +284.62% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $3.62 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $1.34 | +1,765.67% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $0.04 | +187,400.00% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $100.27 | -16.23% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.15 | +2,073.91% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $4.35 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $13.15 | +166.16% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $274.76 | -19.93% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $29.38 | +5.51% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $124.40 | +149.20% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $103.82 | -22.94% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $310.80
Upside: +39.00%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $2.32
Upside: +244.83%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $4.37
Upside: +517.85%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.30
Upside: +398.50%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $35.68
Upside: -7.51%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.77
Upside: +1,481.92%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $18.99
Upside: +42.18%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.82
Upside: +284.62%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $3.62
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $1.34
Upside: +1,765.67%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $0.04
Upside: +187,400.00%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $100.27
Upside: -16.23%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.15
Upside: +2,073.91%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $4.35
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $13.15
Upside: +166.16%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $274.76
Upside: -19.93%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $29.38
Upside: +5.51%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $124.40
Upside: +149.20%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $103.82
Upside: -22.94%